La Jolla’s two main assets are Giapreza, a medication designed to increase blood pressure in patients with septic shock, and Xerava, a treatment for complicated intra-abdominal infections, according to a July 11 press release. The FDA has approved both products for adults.
The transaction is expected to finalize within 30 business days.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
